Progress for European sites in Episurf Medical's Episealer® knee implant IDE study

Episurf Medical (NASDAQ: EPIS B) today announces that the company has secured ethics approval for all European hospitals that are being prepared to take part in the company's clinical study "*EPIC-Knee: Episealer® Knee System IDE Clinical Study*". This includes approval from ethics committees in the UK (four sites), Germany (two sites) and Denmark (one site). Approval from the respective ethics committee is mandatory for the sites to initiate enrollment of patients into the study.

"*This is great progress for our IDE study. The randomised, controlled study includes hospitals in both the US and Europe, with a total number of 180 patients. In the US we have a number of sites totally ready for the study, and in Europe we have now finally gone through all ethic approval processes with favourable outcomes. We are looking forward to starting enrolling IDE patients in the UK, Germany and Denmark*", comments Pål Ryfors, CEO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.00 CET on 12 March 2020.